Doctomatic Signs a Former Doctoralia for its Business in Latin America

Doctomatic builds a team in Latin America. The Spanish company, owned by Doctoralia co-founder Frederic Llordachs, has added Andre Santana to its team to lead the business in the Latin American market, as confirmed by Llordachs.

Santana works for the Spanish company from Mexico. Doctomatic’s new recruit has experience in the digital health sector, as for years he was sales director at Doctoralia in Brazil.

With a degree in Business Administration from Universidade Estadual do Tocantins and an MBA from Fundação Dom Cabral, both in Brazil, Santana comes from Clivi Health, a Mexican company specializing in the diabetes sector, where he worked as marketing and sales director.

Read more about Doctomatic with our companion app. Born2Invest mobile application is bringing all the biotech and business news from trusted sources to a single screen so you can stay on top of the market. The application is aggregating the most important and breaking news from relevant websites, the list is always revised and updated with new resources. 

Doctomatic has raised more than €40,000 in financing

Prior to joining Clivi Health, Santana was director of operations at the Institute for Technological Development in Curitiba. He has also worked for the telecommunications sector in companies such as Claro and Brasil Telecom.

Santana will be responsible, among other tasks, for Doctomatic’s deployment in Latin America, which the company expects to be completed within the next year after having raised more than €400,000. The Doctomatic project was born a year ago with the aim of offering a digital platform for the remote management and control of chronic patients.

The company has raised €415,000 with the support of Carlos Blanco and Oriol Juncosa, both from the Encomenda Smart Capital fund, and Ship2B Ventures, a venture capital firm that invests in start-ups with high social and environmental impact.

The company expects to reach ‘break even’ in 2023 and in five years to bill more than twenty million euros

Doctomatic uses artificial intelligence (AI) capable of reading data from images to know if a person may or may not suffer from a disease. The company’s clients include hospitals, doctors, and insurance companies. Doctomatic’s forecast is to reach break-even in 2023 and in a matter of five years to reach five million patients and a turnover of more than €20 million.

Doctomatic already has agreements with the Suara cooperative to monitor patients with diabetes, hypertension, obesity, or respiratory problems. It is also working with the Korian Spain group of homes for the elderly to monitor remote medicalization, as well as with the Hospital del Mar in Barcelona to monitor patients with heart failure.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.